Gefitinib potentiates myeloid cell differentiation by ATRA. Read more about Gefitinib potentiates myeloid cell differentiation by ATRA.
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Read more about Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
Signal transduction pathways that contribute to myeloid differentiation. Read more about Signal transduction pathways that contribute to myeloid differentiation.
Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. Read more about Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia.
RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Read more about RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia.
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Read more about PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. Read more about Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.
Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission. Read more about Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission.
Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Read more about Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.
Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells. Read more about Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells.
